Melissa S. Hurd

605 total citations
4 papers, 461 citations indexed

About

Melissa S. Hurd is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Melissa S. Hurd has authored 4 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 1 paper in Pathology and Forensic Medicine and 1 paper in Oncology. Recurrent topics in Melissa S. Hurd's work include CRISPR and Genetic Engineering (3 papers), DNA Repair Mechanisms (2 papers) and Epigenetics and DNA Methylation (2 papers). Melissa S. Hurd is often cited by papers focused on CRISPR and Genetic Engineering (3 papers), DNA Repair Mechanisms (2 papers) and Epigenetics and DNA Methylation (2 papers). Melissa S. Hurd collaborates with scholars based in United States and United Kingdom. Melissa S. Hurd's co-authors include Carlo Toniatti, Stuart D. Shumway, Alan Ashworth, Isaac García-Murillas, Nicholas C. Turner, Rachel Sharpe, Heidrun Gevensleben, Marieke Aarts, Amy D. Guertin and Yaping Liu and has published in prestigious journals such as Cancer Research, Cancer Discovery and Molecular Cancer Therapeutics.

In The Last Decade

Melissa S. Hurd

4 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melissa S. Hurd United States	3	397	245	79	44	38	4	461
Neele Drobnitzky United Kingdom	6	421 1.1×	168 0.7×	56 0.7×	49 1.1×	58 1.5×	6	497
Luana D’Artista Italy	7	414 1.0×	228 0.9×	76 1.0×	25 0.6×	54 1.4×	9	496
Joanne M. Munck United Kingdom	10	484 1.2×	180 0.7×	47 0.6×	33 0.8×	68 1.8×	19	556
Janice M. Mehnert United States	8	303 0.8×	183 0.7×	28 0.4×	36 0.8×	58 1.5×	24	409
Jennifer Zlott United States	5	250 0.6×	162 0.7×	34 0.4×	35 0.8×	33 0.9×	18	329
Harish Potu United States	10	364 0.9×	201 0.8×	36 0.5×	13 0.3×	56 1.5×	17	439
Mehlika Hazar-Rethinam Australia	11	321 0.8×	173 0.7×	32 0.4×	67 1.5×	102 2.7×	16	428
Hélène Malka-Mahieu France	6	387 1.0×	136 0.6×	29 0.4×	32 0.7×	51 1.3×	10	456
Hella Anna Bolck Switzerland	9	303 0.8×	125 0.5×	28 0.4×	42 1.0×	89 2.3×	16	362
Chih-Shia Lee United States	8	355 0.9×	139 0.6×	25 0.3×	39 0.9×	65 1.7×	10	421

Countries citing papers authored by Melissa S. Hurd

Since Specialization

Citations

This map shows the geographic impact of Melissa S. Hurd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa S. Hurd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa S. Hurd more than expected).

Fields of papers citing papers by Melissa S. Hurd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa S. Hurd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa S. Hurd. The network helps show where Melissa S. Hurd may publish in the future.

Co-authorship network of co-authors of Melissa S. Hurd

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa S. Hurd. A scholar is included among the top collaborators of Melissa S. Hurd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa S. Hurd. Melissa S. Hurd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Guertin, Amy D., Jing Li, Yaping Liu, et al.. (2013). Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy. Molecular Cancer Therapeutics. 12(8). 1442–1452. 143 indexed citations

2.

Aarts, Marieke, Rachel Sharpe, Isaac García-Murillas, et al.. (2012). Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1. Cancer Discovery. 2(6). 524–539. 252 indexed citations

3.

Guertin, Amy D., Melissa M. Martin, Brian S. Roberts, et al.. (2012). Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell International. 12(1). 45–45. 65 indexed citations

4.

Shumway, Stuart D., Amy D. Guertin, Melissa S. Hurd, et al.. (2011). Abstract 2969: A Wee1 kinase inhibitor, MK-1775, sensitizes cervical carcinoma cell lines to cisplatin and topotecan. Cancer Research. 71(8_Supplement). 2969–2969. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact